Donostia

• OMTX705-006 Phase 1b Recruiting
  2025-521872-69-00 3 2025-10-28 Advanced/Metastatic Pancreatic Adenocarcinoma
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer … Recruiting
  2024-516982-35-00 5 2025-09-11 Ovarian Cancer
• A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain. Recruiting
  2025-521152-34-00 4 2025-09-04 mantle cell lymphoma (MCL)
• Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib … Recruiting
  2025-520743-33-00 9 2025-07-23 Advanced/metastatic colorectal cancer
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlim … Recruiting
  2024-513375-40-00 4 2025-05-16 Melanoma
• Effect of pharmacological treatment with angiotensin receptor/neprilysin inhibitors on transthyretin cardiac amyloidosis and heart failure w … Recruiting
  2024-515661-34-00 6 2025-02-27 Transthyretin cardiac amyloidosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• Efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity Recruiting
  2024-513004-33-00 4 2025-01-14 Hepatotoxicity
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Use of statins in patients with intracerebral hemorrhage Recruiting
  2024-511465-11-00 5 2024-11-20 Spontaneous lobar ICH
• LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Lat … Recruiting
  2024-512835-53-00 4 2024-11-20 Diffuse Large B-Cell Lymphoma
• Continuing Anticoagulants and Antiplatelets in Cold snare Polypectomy. Recruiting
  2024-511265-11-01 6 2024-11-19 patients who are requested a colonoscopy for any indication and are un
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re … Recruiting
  2022-502972-22-00 5 2024-10-31 Clostridioides difficile infection.
• Ampicillin and ceftriaxone for the treatment of Enterococcus faecalis infective endocarditis. Recruiting
  2024-511719-40-00 6 2024-10-09 Enterococcus faecalis infectious endocarditis
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
• Phase 1/2a study of ATX-01 in participants with DM1 Recruiting
  2023-505363-37-00 1 2024-08-12 Myotonic dystrophy type 1 (DM1)
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i … Recruiting
  2023-508204-38-00 5 2024-07-02 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• Multicentric trial on the use of combined therapy of Thiamine and biotine in patients with Huntington´s disease. Recruiting
  2023-508637-14-00 9 2024-06-06 Huntington´s disease.
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer

Showing 49–72 of 202 trials